MedTrace Logo

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

NCT00284804 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2015-10-12

No results posted yet for this study

Summary

This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.

Conditions

  • Hodgkin's Disease

Interventions

DRUG

MDX-060

anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg

Sponsors & Collaborators

Principal Investigators

  • Medarex Medical Monitor · Medarex

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-05-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00284804 on ClinicalTrials.gov